Alpelisib (BYL-719) (Standard) is the analytical standard of Alpelisib ( HY-15244 ). This product is intended for research and analytical applications. Alpelisib (BYL-719) is an orally active PI3Kα -selective inhibitor that blocks the conversion of PIP2 to PIP3 , thereby inhibiting pathways including PI3K/AKT/mTOR , MAPK/ERK , Notch and JAK-STAT . Alpelisib also induces apoptosis , G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin ( HY-13442 ) and exerts a synergistic effect with Paclitaxel ( HY-B0015 ), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer , gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Others | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Metabolic Disease | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > Apoptosis
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye